Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.

Slides:



Advertisements
Similar presentations
Dinkar Kaw, M.D., Division of Nephrology
Advertisements

Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Prepared by D. Chaplin Chronic Renal Failure. Prepared by D. Chaplin Chronic Renal Failure Progressive, irreversible damage to the nephrons and glomeruli.
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.
The PREVEND Study: Screening for micro-albuminuria
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
DIABETES AND THE KIDNEYS
CKD In Primary Care Dr Mohammed Javid.
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.
Chapter 2: Healthy People A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Early detection, prediction and potential treatment.
Welch Center Uniting Medicine & Public Health Prevalence of Albuminuria, and its Relationship to Decreased GFR and Outcomes Josef Coresh, MD, PhD Director,
Managing Chronic Kidney Disease in the Elderly Veteran Ann M. O’Hare, MA MD Staff Physician, VAPSHCS Assistant Professor of Medicine University of Washington.
Chapter 2: Identification and Care of Patients With CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
Diabetes Mellitus Type 2
Lesley Stevens MD Tufts-New England Medical Center
Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.
Diabetic Nephropathy Case Presentations. UA (Urine Dipstick) Use as an initial screen for all patients Negative to trace proteinuria requires further.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
RENAL DISEASE IN DIABETES
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
SM Gatmiri, MD, Nephrologist Imam Khomeini Hospital,
New Concepts in Chronic Kidney Disease Jonathan B. Jaffery, MD Assistant Professor of Medicine University of Wisconsin-Madison.
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
Shadi Al-Ahmadi. The Presentation will include: Hypertension Dyslipidemia CVD Type 2 Diabetes-Associated Retinopathy Diabetic Periphral Neuropathy Diabetic.
Diabetic Nephropathy in the Adolescent Age Group Henry Rodriguez, M.D. Associate Professor of Pediatrics Indiana University School of Medicine Director,
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Healthy People 2010 Focus Area 4
2-4. Estimated Renal Function Estimated GFR = 1.8 x (Cs) x (age) Cockcroft-Gault eq. – Estimated creatine clearance (mL/min) = (140 – age x body weight,
Hypertension Control and Progression of Renal Disease
Chapter 2: Identification and Care of Patients With CKD 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Predicting Progression in Diabetic Nephropathy: New Biomarker: sTNFR1* Circulating soluble Tumor Necrosis Factor Receptor 1.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 2: Healthy People 2020.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
1 به نام خدا. Epidemiology of chronic kidney disease 2.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
Professor Tazeen H Jafar Duke-National University of Singapore & Aga Khan University, Karachi, Pakistan Chronic Kidney Disease- Integration into the NCD.
Updates in Diabetic Nephropathy Rodica Pop-Busui, M.D., Ph.D Division of Metabolism, Endocrinology and Diabetes Michigan Comprehensive Diabetes Center.
Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Sickle Cell Trait With Chronic Kidney.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
Section 2: Detection of CKD
The Significance of Albuminuria
What should the Systolic BP treatment goal be in patients with CKD?
Section 4: Managing progression of CKD
2017 Annual Data Report Healthy People 2020.
Chapter 1: CKD in the General Population
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease    American Journal of Kidney Diseases 
2018 Annual Data Report Volume 3: Healthy People 2020
Recent studies of ACE inhibition in renal disease
Chapter 1: CKD in the General Population
Section I: RAS manipulation
به نام خدا.
Meeting the challenges of the new K/DOQI guidelines
Table of Contents Why Do We Treat Hypertension? Recommendation 5
American Journal of Kidney Diseases
Presentation transcript:

Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH

Scope of the Problem u The incidence of End-stage renal disease is growing u As of 12/31/98, there were more than 200,000 people in the US on dialysis* u End-stage renal disease care accounted for >16 billion dollars in 1998* u The major causes of ESRD are diabetes (45%) and hypertension (24%) and are therefore potentially preventable u ESRD disproportionately affects minorities and the elderly *USRDS

Incident rates of ESRD Due to Diabetes & Hypertension, by Race Rate per million population, adjusted for age & gender USRDS

Incident Rates, by Age & First Modality adjusted for gender & race USRDS

Incident Rates, by Primary Diagnosis & First Modality adjusted for age, gender, & race USRDS

Identifying People with Early Renal Disease u Proteinuria –Microalbuminuria –Overt Proteinuria/Albuminuria- associated with lower Creatinine clearance in population* u Serum Creatinine- miss early declines in GFR u Creatinine Clearance- difficult to do as screen u Estimated glomerular filtration rate (GFR) - formulas from laboratory/clinical variables *Pinto-Sietsma et al, Groningen, Netherlands, JASN 2000

Proposed NKF Clinical Practice Guideline for Stages of Kidney Disease

* Proteinuria, Urinary sediment abnormalities, Structural abnormalities, Alterations in composition of the urine

Proteinuria u The level of proteinuria is a prognostic factor in renal disease u This is true for a wide variety of diseases, including hypertensive renal diseases u Easily performed –Urine dipstick –Albumin sticks –Protein or albumin/creatinine ratio on spot urine

Should we be screening for proteinuria or an elevated creatinine? u All diabetics should be screened for microalbuminuria - ADA and NKF recommendation u In the US, the prevalence of proteinuria is low in subjects without hypertension or diabetes u US Preventive Health Services Task Force does not recommend urinalysis or creatinine as screen in otherwise healthy adults u Are there higher risk groups, such as African Americans or older individuals where screening should be done in asymptomatic individuals without diabetes or hypertension?

Prevalence of Albuminuria in Individuals Without Diabetes: NHANES III

Prevalence of an Increased Creatinine* in Normal, High Normal, and Stage 1 Hypertension : NHANES III *Cr  1.6 men, 1.4 women, Coresh et al, Arch Intern Med 2001

Screening for Renal Disease u Many of those with early renal disease have not been informed of the diagnosis –In a small pilot study, only 36% (9 of 25) of patients with a creatinine between 1.5 and 3.0 knew of their renal disease

Screening for Renal Disease u Microalbuminuria –Risk factor for cardiovascular events and in nondiabetics this may be a reason to screen, especially in the elderly –It is a risk factor for progression of diabetic nephropathy, unknown if it is a risk factor in nondiabetics u Overt proteinuria also identifies those at risk for subsequent events* u An elevated creatinine identifies not only those at risk for progression of renal disease, but also those at higher risk for mortality and cardiovascular events *NHANES 1, Wagener et al Environ Res 1994

Cardiovascular Health Study u Population-based, longitudinal study of 5,888 individuals, age >65 years u Random sample from Medicare eligibility lists in: –Pittsburgh, PA –Forsyth County, NC –Washington County, MD –Sacramento County, CA u Primary objective of CHS is to identify risk factors related to coronary heart disease and stroke

Elderly with Renal Insufficiency YES 36% NO 64% YES 28% NO 36% YES 2% NO 34% YES 6% NO 28% N=208N=370 N=161 N=209 N=14N=195 N=32N=163 Clinical CV Disease Subclinical CV Disease Diabetes Mellitus Framingham Risk > 20% / 10 years N=578 Baseline Cardiovascular Risk in Subjects with an Elevated Creatinine (  1.5 men or 1.3 women)

Survival of Elderly Subjects in CHS by Baseline Creatinine Level

Relative Risk for Cardiovascular Disease: Unadjusted and Fully Adjusted Models

Preventing Decline in Renal Function u Hypertension Control u Angiotensin Converting Enzyme Inhibitors/ Angiotensin Receptor Blockers u Control of Diabetes u Lipid Reduction u Smoking cessation- smoking is associated with a faster decline, no intervention studies u Low Protein Diet- falling out of favor

Multifactorial Intervention Slows Progression to Nephropathy in Diabetes: Steno Study u 160 Type 2 Diabetes, stratified by level of proteinuria (30-100mg/day, mg/day) u Randomized to standard or intensive management u Intensive Therapy: behavioral modification (diet, exercise, smoking cessation) and pharmacologic therapy in step-wise fashion u Primary endpoint was nephropathy (albumin excretion rate >300mg/24 hours) Lancet 1999

Steno Study Treatment Goals

Steno Results u 8 patients (11%) in intensive vs 19 (25%) in standard therapy grouped developed overt nephropathy after 4 years (p=0.01) u No patient developed end-stage renal disease u Lower risk of progression, but not development of retinopathy u Lower risk of progression of autonomic neuropathy u No difference in CVD events, though numbers were small u Trend towards fewer patients developing a drop in AAI